4568 Stock Overview
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 4568 from our risk checks.
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥4,972.00 |
52 Week High | JP¥5,173.00 |
52 Week Low | JP¥3,566.00 |
Beta | 0.30 |
1 Month Change | -2.64% |
3 Month Change | 28.41% |
1 Year Change | 7.16% |
3 Year Change | 54.17% |
5 Year Change | 177.77% |
Change since IPO | 544.32% |
Recent News & Updates
Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year
Mar 11Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00
Feb 26Shareholder Returns
4568 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | 1.7% | -0.6% | 1.0% |
1Y | 7.2% | 16.6% | 38.6% |
Return vs Industry: 4568 underperformed the JP Pharmaceuticals industry which returned 16.6% over the past year.
Return vs Market: 4568 underperformed the JP Market which returned 38.6% over the past year.
Price Volatility
4568 volatility | |
---|---|
4568 Average Weekly Movement | 4.2% |
Pharmaceuticals Industry Average Movement | 3.8% |
Market Average Movement | 3.9% |
10% most volatile stocks in JP Market | 8.3% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4568 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4568's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1899 | 17,435 | Sunao Manabe | https://www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol.
Daiichi Sankyo Company, Limited Fundamentals Summary
4568 fundamental statistics | |
---|---|
Market cap | JP¥9.53t |
Earnings (TTM) | JP¥186.05b |
Revenue (TTM) | JP¥1.50t |
51.2x
P/E Ratio6.3x
P/S RatioIs 4568 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4568 income statement (TTM) | |
---|---|
Revenue | JP¥1.50t |
Cost of Revenue | JP¥416.74b |
Gross Profit | JP¥1.09t |
Other Expenses | JP¥900.68b |
Earnings | JP¥186.05b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | 97.03 |
Gross Margin | 72.28% |
Net Profit Margin | 12.37% |
Debt/Equity Ratio | 6.4% |
How did 4568 perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield36%
Payout RatioDoes 4568 pay a reliable dividends?
See 4568 dividend history and benchmarksDaiichi Sankyo Company dividend dates | |
---|---|
Ex Dividend Date | Mar 28 2024 |
Dividend Pay Date | Jun 20 2024 |
Days until Ex dividend | 0 days |
Days until Dividend pay date | 84 days |
Does 4568 pay a reliable dividends?
See 4568 dividend history and benchmarks